The aim of this study was to evaluate the clinical efficacy of standardized French maritime pine bark extract Pycnogenol® in patients with severe chronic venous insufficiency (CVI). 98 subjects with symptomatic CVI and edema were randomly assigned to one group treated with 150mg Pycnogenol a day only, another group with stockings only and a third group with both Pycnogenol and elastic stockings. The average ambulatory venous pressure (AVP) at inclusion was 58±7mmHg (range 48–60mmHg) with a refilling time (RT) < 12 s (average 7±2 s). The duration of the disease was on average 6.0±3.1 years. There were no differences in AVP or RT among the 3 groups at inclusion and microcirculatory and clinical evaluations were comparable. After 8 weeks treatment there was a significant decrease of rate of ankle swelling, resting flux, transcutaneouspO2 and clinicalsymptomscores in all groups with significantly better results for the combination treatment. Pycnogenol alone was more effective than compression alone for all parameters (p < 0.05). No side-effects were observed; compliance and tolerability were very good. This study corroborates a significant clinical role for Pycnogenol in the management, treatment and control of CVI also in combination with compressi

Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study

BELCARO, Giovanni;CACCHIO, Marisa Adriana;
2010-01-01

Abstract

The aim of this study was to evaluate the clinical efficacy of standardized French maritime pine bark extract Pycnogenol® in patients with severe chronic venous insufficiency (CVI). 98 subjects with symptomatic CVI and edema were randomly assigned to one group treated with 150mg Pycnogenol a day only, another group with stockings only and a third group with both Pycnogenol and elastic stockings. The average ambulatory venous pressure (AVP) at inclusion was 58±7mmHg (range 48–60mmHg) with a refilling time (RT) < 12 s (average 7±2 s). The duration of the disease was on average 6.0±3.1 years. There were no differences in AVP or RT among the 3 groups at inclusion and microcirculatory and clinical evaluations were comparable. After 8 weeks treatment there was a significant decrease of rate of ankle swelling, resting flux, transcutaneouspO2 and clinicalsymptomscores in all groups with significantly better results for the combination treatment. Pycnogenol alone was more effective than compression alone for all parameters (p < 0.05). No side-effects were observed; compliance and tolerability were very good. This study corroborates a significant clinical role for Pycnogenol in the management, treatment and control of CVI also in combination with compressi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/205733
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 41
social impact